(UroToday.com) The European Association of Urology (EAU) 2021 Virtual Annual Meeting included a joint session of the EAU and the Canadian Urological Association and a presentation by Dr. Frederic Pouliot suggesting that prostate radioligand therapy is only a tessera in the treatment of CRPC. Dr. Pouliot notes that theranostics is the combination of imaging and therapy, most commonly 177Lu-PSMA radioligand therapy. Radioligand therapy is promising, but Dr. Pouliot poses: is it really as simple as PSMA PET positive disease = PSMA radioligand targetable = PSA response = clinical benefits?